Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 48

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Psoriasis

Not yet recruiting

Long-term Safety and Efficacy of ORKA-001 in Adults with Moderate-to-Severe Plaque Psoriasis (Open-Label Extension Study)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years

Dermatitis atopic

Not yet recruiting

A Phase 2b Study Evaluating the Efficacy and Safety of ENV-294 in Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Ocular myasthenia

Not yet recruiting

A Phase 3 Randomized Study of Rozanolixizumab for Safety and Efficacy in Adults with Ocular Myasthenia Gravis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Dermatitis atopic+1

Not yet recruiting

Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Dermatitis atopic

Not yet recruiting

Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Multiple sclerosis+1

Not yet recruiting

Study of Lactobacillales and Lacidofil in Multiple Sclerosis Patients: Comparing Effectiveness of Probiotic Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy

Asthma

Not yet recruiting

Study comparing fluticasone furoate and vilanterol inhalation powder with BREO ELLIPTA in adults with asthma to evaluate their therapeutic equivalence and safety

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fluticasone Furoate
  • Sponsor:Sandoz Private Limited

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.